vax014
Recombinant proteinexperimental
Clinical trial activity
2 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started May 10, 2019 (NCT03854721)
Timeline
2010s
- Jan 1, 2019
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Fibronectin receptor betaANTAGONIST
ITGB1 antagonist
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05901285 | Phase 1 | Nov 2, 2023 | Vaxiion Therapeutics |
| NCT03854721 | Phase 1 | May 10, 2019 | Vaxiion Therapeutics |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Vaxiion Therapeutics | For profit | 2 | 2 | 1 | 2019 |
1 organizations
Page 1 / 1